~~<i id='4BDCE80DE3'><strike id='4BDCE80DE3'><tt id='4BDCE80DE3'><pre id='4BDCE80DE3'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

leisure time

author：knowledge 2025-10-02 19:15:57 - browse：414

Blue nerve cell surrounded by red antibodies. -- health coverage from STAT — Adobe

Belgian drugmaker Argenx said Monday that its antibody treatment called Vyvgart significantly delayed the progression of an autoimmune nerve disorder that causes people to lose feeling and muscle strength in the arms and legs.

The positive outcome — a 61% reduction in the risk of relapse compared to a placebo — achieved the main goal of a Phase 3 clinical trial designed to demonstrate Vyvgart’s benefit for patients with chronic inflammatory demyelinating polyneuropathy, or CIDP.

“We hit the bullseye,” said Argenx CEO Tim Van Hauwermeiren.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Test for long Covid? Researchers find new clue in blood samples

hotspot

explore

leisure time

AdobeDewpointTherapeutics,thebuzzieststartuptryingtotackleanewfieldofbiologycalledbiomolecularconden

WSS

Biotech venture capitalists face new demands from investors

Eli Lilly, Pfizer, and others want in on the online prescription market

Elizabeth Holmes banned from government health programs

Research misconduct: Proposed new rules face resistance

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

EU regulator recommends expanding Mounjaro approval to obesity

hotspot

leisure time

hotspot

Guidelines to prevent youth baseball injuries need more muscle

My yearlong odyssey to get my son’s ADHD medication covered

23andMe had bad news about my health. I wish a person had delivered it

Test for long Covid? Researchers find new clue in blood samples

Hepatitis C has a cure — but many Americans still lack access to it

Biotech venture capitalists face new demands from investors

In Memoriam: Notable people who died in 2023

Dewpoint Therapeutics lays off staff after losing partnerships

Medicare proposal to cover medical devices draws a mixed reaction

Research misconduct: Proposed new rules face resistance

hotspot

Elizabeth Holmes banned from government health programs

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Francis Collins on trust in science and how Covid communications failed

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Copay coupons to count toward deductibles, after Biden court move

explore

explore

leisure time

leisure time